维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Samuel Nussbaum"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Superior mesenteric venous thrombosis: Endovascular management and outcomes显示文摘BACKGROUND Superior mesenteric venous thrombosis(SMVT)is a rare but fatal condition that is typically treated initially with anticoagulation therapy,and if this fails,with endovascular interventions.However,due to its rarity,there are not many studies that have explored the effectiveness of anticoagulation and endovascular therapies in treating SMVT.AIM To evaluate patients diagnosed with SMVT who received endovascular therapy in addition to anticoagulation and report technical and clinical outcomes.METHODS A retrospective analysis of the patients who underwent endovascular treatment for SMVT at Mayo Clinic from 2000-2019 was performed.Technical success was defined as angiographic improvement in SMV flow after intervention.Primary patency was defined as the interval from reestablishing mesenteric venous flow until the first repeat thrombotic event or need for additional intervention.Secondary patency was defined as successful restoration of flow after repeat intervention until rethrombosis or last follow-up.The adverse events were reported through Clavien-Dindo classification.RESULTS Twenty-four patients were included for analysis.The median age at intervention was 60 years(35-74 years)and 16(67%)were men.Nineteen patients presented with acute thrombosis(79.2%)and 5 with chronic thrombosis with acute manifestations(20.8%).The most commonly used endovascular modalities were thrombectomy in 12 patients(50.0%)and catheter-directed thrombolysis in 10 patients(41.7%).Technical success was achieved in 18 patients(75%).The 14-d and 30-d primary patency rates were 88.9%and 83.3%,respectively.Adverse events were reported in two patients(8.3%),one marked as grade IIIB,and 1 death marked as grade V.Five-year overall survival rate was 82%(58%-100%).CONCLUSION Endovascular intervention with anticoagulation appears to be effective for managing SMVT.This treatment combination may be considered as first-line therapy for SMVT management in select patients.	Khaled Alnahhal Beau B Toskich Samuel Nussbaum Zhuo Li Young Erben Albert G Hakaim Houssam Farres	2022	World Journal of Clinical Cases2022，10，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费